Next-Gen Kinase Inhibitors

TOPIC HIGHLIGHTS 

Designing, Screening and Assessing Selectivity 

Identifying and Assaying Allosteric Kinase Inhibitors 

Covalent Inhibition 

Kinases for CNS Indications – An Exciting Challenge 

Inflammation& Autoimmune – Leading Programs 

Kinases in Oncology – PI3, mTOR, cMet  & More 

Novel Kinase Targets in Hot Pursuit 

Screening & Monitoring DMPK and Tox 

Advances in Computational Methods 

Resistance – Future Challenges 

Click here for the final agenda 

Distinguished Faculty 

Mark Ashwell, ArQule Inc
James Blake, Array BioPharma, Inc.
Peter Brandt, Beactica AB
Stephen K. Burley, Eli Lilly & Company
Dirksen Bussiere, Novartis Vaccines & Diagnostics Inc.
Josette Carnahan, Amgen
Kenneth Comess, Abbott Laboratories
Jean Cui, Pfizer, Inc.
Greg Cuny, Brigham & Women’s Hospital
David C. Dalgarno, ARIAD Pharmaceuticals Inc.
David H. Drewry, GlaxoSmithKline
Isabelle Dussault, Amgen
Doriano M. Fabbro, Novartis Institutes for BioMedical Research
Jordan S. Fridman, Incyte Corp.
Daniel Goldberg, Karos Pharmaceuticals, Inc.
Andrew C. Good, Genzyme Corp
John D. Haley, OSI Pharmaceuticals
Stephanos Ioannidis, AstraZeneca
Ronald Knegtel, Vertex Pharmaceuticals (Europe) Ltd.
Ravi G. Kurumbail, Pfizer, Inc.
Chris Liang, Xcovery, LLC
Carol MacKintosh, University of Dundee
Henrik Mobitz, Novartis
Yibing Shan, D. E. Shaw Research
Juswinder Singh, Avila Therapeutics, Inc.
Rajinder Singh, Rigel Pharmaceuticals Inc.
Kent Stewart, Abbott
Eli Wallace, Array BioPharma
Neil Wishart, Abbott
Paul Yu, Massachusetts General Hospital
Donald Zack, Johns Hopkins University School of Medicine
 

Co-Located with:11th Annual Structure-Based Drug Design Conference
June 8-10